Laboratoire de Virologie, AP-HP Groupe hospitalier Bichat-Claude Bernard and EA 4409 Université Paris-Diderot, Paris 7, PRES Sorbonne Paris Cité, Paris, France.
J Antimicrob Chemother. 2013 Nov;68(11):2626-31. doi: 10.1093/jac/dkt238. Epub 2013 Jun 24.
As recommended by the French ANRS programme for the surveillance of HIV-1 resistance, we estimated the prevalence of transmitted drug resistance-associated mutations (RAMs) in antiretroviral-naive, chronically HIV-1-infected patients.
RAMs were sought in samples from 661 newly diagnosed HIV-1-infected patients in 2010/11 at 36 HIV clinical care centres. Weighted analyses were used to derive representative estimates of the percentage of patients with RAMs.
At patient inclusion, the prevalence of virus with protease (PR) or reverse transcriptase (RT) RAMs was 9.0% (95% CI 6.8%-11.2%). No integrase RAMs were observed. The prevalences of protease inhibitor, nucleoside RT inhibitor and non-nucleoside RT inhibitor RAMs were 1.8%, 6.2% and 2.4%, respectively. Resistance to one, two and three classes of antiretroviral agent was observed in 7.9%, 0.9% and 0.2% of patients, respectively. The frequency of RAMs was higher in patients infected with B compared with non-B subtype virus (11.9% versus 5.1%, P = 0.003). Baseline characteristics (gender, age, country of transmission, CD4 cell count and viral load) were not associated with the prevalence of transmitted RAMs. However, men having sex with men (MSM) were more frequently infected with resistant virus than were other transmission groups (12.5% versus 5.8%, P = 0.003). Compared with the 2006/07 survey, the overall prevalence of resistance remained stable. However, a significant decrease in the frequency of virus with PR RAMs was observed in 2010/11 compared with the 2006/07 survey (1.8% versus 5.0%, P = 0.003).
In France in 2010/11, the global prevalence of transmitted drug-resistant variants was 9.0%, and the prevalence was stable compared with the 2006/07 survey. MSM and B subtype-infected patients are the groups with a higher prevalence of drug resistance.
根据法国抗逆转录病毒治疗监测研究网络（ANRS）计划的建议，我们评估了新诊断为 HIV-1 感染且未接受过抗逆转录病毒治疗的慢性 HIV-1 感染者中传播相关耐药突变（TRAMs）的流行率。
在 2010/11 年，对 36 个 HIV 临床护理中心的 661 例新诊断 HIV-1 感染患者的样本进行了 TRAMs 检测。采用加权分析计算了携带 TRAMs 的患者比例的代表性估计值。
在患者入组时，蛋白酶（PR）或逆转录酶（RT）区域有 TRAMs 的病毒流行率为 9.0%（95%CI：6.8%-11.2%）。未观察到整合酶区 TRAMs。蛋白酶抑制剂、核苷逆转录酶抑制剂和非核苷逆转录酶抑制剂 TRAMs 的流行率分别为 1.8%、6.2%和 2.4%。有 7.9%、0.9%和 0.2%的患者分别对 1、2 和 3 类抗逆转录病毒药物耐药。与非 B 亚型病毒感染患者相比，B 亚型病毒感染患者的 TRAMs 频率更高（11.9%比 5.1%，P=0.003）。基线特征（性别、年龄、传播途径、CD4 细胞计数和病毒载量）与传播相关的 TRAMs 流行率无关。但是，男男性行为（MSM）者感染耐药病毒的比例高于其他传播组（12.5%比 5.8%，P=0.003）。与 2006/07 年调查相比，整体耐药率保持稳定。然而，与 2006/07 年调查相比，2010/11 年 PR 区域的耐药病毒频率显著降低（1.8%比 5.0%，P=0.003）。
在 2010/11 年的法国，传播相关耐药变异体的全球流行率为 9.0%，与 2006/07 年调查相比保持稳定。MSM 和 B 亚型感染者是耐药率较高的群体。
